dir-labeled metacell  (MetaCell Inc)

Journal: Biomaterials Research

Article Title: Copper-Based Nanomedicines for Cuproptosis-Mediated Effective Cancer Treatment

doi: 10.34133/bmr.0094

Figure Lengend Snippet: Enhancing cuproptosis in breast cancer metastasis inhibition and rechallenge resistance through combination therapy with type-I AIE photosensitizer loaded biomimetic system. (A) Schematic illustration of a type-I AIE photosensitizer integrated into a biomimetic system to trigger cancer cuproptosis. (B) Transmission electron microscopy images of Cu 2 O and PTC. Scale bars: 50 nm. (C) Alterations in the concentration of copper ions within cells following incubation with various formulations. (D) DLAT fluorescence images of cancer cells posttreatment as specified. DLAT aggregation is highlighted by white arrows. PC: PM-coated Cu 2 O without TBP-2. Scale bars: 15 μm. (E) DLAT fluorescence images of cancer cells post PTC+L treatment with varying concentrations of Cu 2 O. DLAT aggregation is highlighted by white arrows. Scale bars: 15 μm. (F) Analysis of cellular apoptosis in 4T1 cells following treatment with various formulations. (G) Changes of tumor volume in mice after undergoing diverse treatments for tumor metastasis. (H and I) The ratio of central memory T cells (TCM, CD62L + , CD44 + ) to CD3 + , CD8 + T cells in the bloodstream 14 d post PTC treatment for tumor rechallenge assessed via flow cytometry. Reproduced from with permission from American Chemical Society, Copyright 2023.

Article Snippet: After intravenous injection into 4T1 orthotopic breast tumor model, DiR-labeled MetaCell showed superior tumor-targeting ability compared to DiR-labeled Lip@Fe-Cu-MOFs for 7 d, resulting in exhibiting 1.55-fold higher fluorescence intensity than DiR-labeled Lip@Fe-Cu-MOFs (Fig. F and G).

Techniques: Inhibition, Transmission Assay, Electron Microscopy, Concentration Assay, Incubation, Fluorescence, Flow Cytometry

Journal: Biomaterials Research

Article Title: Copper-Based Nanomedicines for Cuproptosis-Mediated Effective Cancer Treatment

doi: 10.34133/bmr.0094

Figure Lengend Snippet: Lip@Fe-Cu-MOFs-internalized neutrophil (MetaCell)-mediated synergistic cuproptosis and ferroptosis-based treatment of malignancies. (A) Design and preparation of MetaCell. (B) Schematic illustration of synergistic anticancer effects of cuproptosis and ferroptosis induced by MetaCell. (C) CLSM images of MetaCell after incubation with Lip@Fe-Cu-MOFs. Scale bars: 10 μm. (D) In vitro anticancer effects of MetaCell on 4T1 cells under various treatments. (E) Western blot analysis of DLAT, LIAS, FDX1, and GPX4 expression levels in 4T1 cells, wherein (1) was treated with neutrophils or (2) MetaCell with phorbol-12-myristate-13-acetate (PMA) and NIR irradiation. (F) In vivo tumor targeting ability of MetaCell targeting in 4T1 tumor-bearing. (G) Biodistribution of DiR-labeled Lip@Fe-Cu-MOFs and MetaCell in tumors and major organs on 7 d postadministration. (H) Representative tumor tissue section images stained with hematoxylin and eosin, ROS, GPX4, and DLAT after treatment. Scale bars: 100 μm. Reproduced from with permission from the American Association for the Advancement of Science, Copyright 2024.

Article Snippet: After intravenous injection into 4T1 orthotopic breast tumor model, DiR-labeled MetaCell showed superior tumor-targeting ability compared to DiR-labeled Lip@Fe-Cu-MOFs for 7 d, resulting in exhibiting 1.55-fold higher fluorescence intensity than DiR-labeled Lip@Fe-Cu-MOFs (Fig. F and G).

Techniques: Incubation, In Vitro, Western Blot, Expressing, Irradiation, In Vivo, Labeling, Staining